(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 150.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 277.12%, and while it is forecast to beat the US market's average forecast revenue growth rate of 58.4%.
Tonix Pharmaceuticals Holding's revenue in 2025 is $10,299,000.On average, 5 Wall Street analysts forecast TNXP's revenue for 2025 to be $122,393,601, with the lowest TNXP revenue forecast at $100,406,797, and the highest TNXP revenue forecast at $141,789,566. On average, 5 Wall Street analysts forecast TNXP's revenue for 2026 to be $1,040,575,251, with the lowest TNXP revenue forecast at $289,479,179, and the highest TNXP revenue forecast at $2,516,411,495.
In 2027, TNXP is forecast to generate $1,079,508,499 in revenue, with the lowest revenue forecast at $556,700,693 and the highest revenue forecast at $1,626,104,919.